Oncology has undergone remarkable changes in the past decades and has entered the era of precise medicine and personalized treatment. Cancer management is increasingly dependent on accurate diagnosis and cancer prevention. Although cancer diagnosis still largely relies on pathology, medical imaging, and other tests, molecular diagnostics is expanding in this territory. In this Editorial, we will briefly discuss the role of molecular diagnostics in cancer diagnosis and management.
Editorial
Oncology has undergone remarkable changes in the past decades and has entered the era of precise medicine and personalized treatment. Cancer management is increasingly dependent on accurate diagnosis and cancer prevention. Although cancer diagnosis still largely relies on pathology, medical imaging, and other tests, molecular diagnostics is expanding in this territory. In this Editorial, we will briefly discuss the role of molecular diagnostics in cancer diagnosis and management.
Cancer is essentially a disease of the genome. Alterations in oncogenes, tumor-suppress or genes and stability genes are responsible for tumorigenesis. So far, about 300 cancer genes have been reported, constituting more than 1% of all the genes in the human genome. About 90% of cancer genes show somatic mutations in cancer, 20% show germline mutations and 10% show both [1] . Molecular diagnostics is a collection of techniques that analyze genetic materials, proteins, or related molecules and thus provide information about health and disease. It is a fundamental component of precision medicine. In cancer diagnosis and therapy, molecular diagnostics contributes in the following ways: to determine whether a person is at risk for a certain type of cancer; to help diagnose cancers or differentiate cancers from benign tumors; to determine blood cancer subtypes; to help predict whether patients will respond to cancer treatments; to evaluate the likelihood that an existing cancer will recur after treatment.
In personalized therapy for advanced non-small cell lung cancer (NSCLC), for example, molecular analyses play a vital role. Patients with sensitizing mutations in the epidermal growth factor receptor (EGFR) experience improved progress-free survival and response rates with first-line gefitinb or erlotinib therapy relative to traditional platinum-based chemotherapy, while patients with EGFR-mutation negative tumors gain greater benefit from platinum-based chemotherapy [2] . Anaplastic lymphoma kinase (ALK) disorders are shown to cause about 5% of NSCLC, therefore, ALK tyrosine kinase receptors are therapeutic targets in NSCLC and other malignancies with ALK fusion [3] . Molecular diagnostics can be repeated over the course of treatment in order to monitor treatment response and signs of recurrence. In ALK-positive patients, molecular diagnostics can identify those who might develop resistance to initial ALK inhibitor (e.g., crizotinib) treatment, and to whom new generation inhibitors (e.g., ceritinib and alectinib) should be administered accordingly. The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology have published a guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors [4] . This guideline makes recommendations on testing for EGFR mutations and ALK fusions to guide patient selection for therapy, and is endorsed by the American Society of Clinical Oncology [5] . Volume 1 , Issue 1, Article ID: 100001 DNA sequencing is one of the most important molecular diagnostics technologies. Sanger sequencing, developed by Edward Sanger [6] , was considered the gold standard for nucleic acid sequencing for nearly three decades. Although incremental improvements reduced the cost of Sanger sequencing and allowed laboratories to add contents to their tests, it is the massive parallel sequencing technique that facilitates high throughput sequencing [7] . This second generation sequencing, or next generation sequencing (NGS), allows whole genome or several genomes to be sequenced in a short time period. Some of the NGS technologies emerged in the 1990's and became commercially available since 2005. The past decade witnessed a revolution in sequencing technologies that is considered one of the most significant technological advances in the biological sciences in the recent years [8] .
Targeted DNA enrichment methods allow even higher genome throughput at a reduced cost per sample. NGS is implemented by many laboratories for routine diagnostics, and the application of NGS in cancer leads to tremendous advances in cancer diagnosis and personalized therapy.
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